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METHODS AND MATERIALS: The American Brachytherapy Society and Groupe Europeen de
Curietherapie/European Society for Therapeutic Radiation and Oncology convened a group of
expert practitioners and physicists to develop a statement for the use of 192Ir in low-dose-rate
(LDR), pulse-dose-rate, and high-dose-rate (HDR) brachytherapy for penile cancer.
RESULTS: Decades of brachytherapy experience with LDR 192Ir wire and pulse-dose-rate 192Ir
sources for this rare malignancy indicate a penile preservation rate of 70% at 10 years postimplant.
Chief morbidities remain stenosis of the urethral meatus and soft tissue ulceration at the primary
site. Nonhealing ulceration can be successfully managed with various measures including hyper-
baric oxygen treatment. HDR brachytherapy implant procedures are technically similar to LDR.
The optimal HDR dose and fractionation schemes are being developed.
CONCLUSIONS: The good tumor control rates, acceptable morbidity, and functional organ pres-
ervation warrant recommendation of brachytherapy as the initial treatment for invasive T1, T2, and
selected T3 penile cancers.  2013 American Brachytherapy Society. Published by Elsevier Inc. All
rights reserved.Keywords: Penile carcinoma; Interstitial brachytherapy; Low-dose-rate brachytherapy; Pulse-dose-rate brachytherapy;High-dose-rate brachytherapyIntroduction
The Board of the American Brachytherapy Society
(ABS) invited a leading author in the field (JMC) to draft
a statement for penile brachytherapy with international
participation. CH-M was invited to coauthor the statement.012; received in revised form 30 November 2012;
013.
author. Department of Radiation Oncology, British
ency Cancer, Center for the Southern Interior, 399
na, BC V1Y 5L3, Canada. Tel.: þ1-250-712-3979;
.
crook@bccancer.bc.ca (J.M. Crook).
nt matter  2013 American Brachytherapy Society. Publis
.1016/j.brachy.2013.01.167Subsequently, review and input were sought from those
practitioners personally known to have experience in the
field (AAM, DJD, and JJM). The final draft was approved
by the ABS Board of Directors and by the Groupe Europeen
de Curietherapie and the European Society of Therapeutic
Radiation and Oncology Council. Literature review revealed
an absence of randomized studies. One multicenter retro-
spective review from Rozan et al. (1) in France and a handful
of reported series from single institutions provide Level
3 evidence. Nonetheless we believe this consensus statement
will provide valuable guidance.
Squamous cell carcinoma of the penis is a relatively rare
malignancy in the developed world, with an incidence ofhed by Elsevier Inc. All rights reserved.
192 J.M. Crook et al. / Brachytherapy 12 (2013) 191e198approximately 1 per 100,000 men (2), although much high-
er in some third world countries being more than 4 per
100,000 in Paraguay (3), and cited as up to 1% by age of
75 years in some parts of Uganda (4). It is highly curable
in its early stages. Surgical amputation (penectomy) is
often the first or only treatment method considered, but
traditional amputative surgery is associated with a high
level of psychosexual morbidity (5e7). Surgery, however,
is not the only potentially curative treatment. Organ-
sparing definitive radiation therapy, with or without local
resection, can provide both cure and a high rate of penile
preservation. Many urologists may only see one or two
cases in a lifetime of practice, so awareness of this thera-
peutic alternative may be limited. Because penile-sparing
approaches are being used more frequently in centers with
experience, referral to such centers is recommended. This
review is designed to inform radiation oncologists, urolo-
gists, and other physicians about the role of radiation
therapy in the treatment of carcinoma of the penis.Patient evaluation
Carcinoma of the penis is most frequently located on the
glans and prepuce (8). It occurs much more frequently in
uncircumcised men, although human papillomaviruse
associated cases have been reported in men circumcised
as neonates (9). The first step in evaluation is to obtain
a tissue biopsy, preferably deep enough to show the extent
of invasion (10). Next, one must ensure full visibility of the
lesion, which is often hidden under a phimotic foreskin
(11). This step consists of either circumcision or a dorsal
slit incision to expose the lesion, prevent soft tissue stran-
gulation and tissue necrosis, and to promote hygiene. When
possible, along with circumcision, local tumor excision can
be performed to remove gross tumor and necrotic debris.
These excisions must be done in a manner that preserves
the cosmetic and functional integrity of the penis. Wound
healing is usually adequate to allow brachytherapy to
proceed within 10e14 days.
A complete history and physical examination to assess
comorbidities and a workup to rule out metastatic disease
are needed. Particular attention should be given to theTable 1
TNM primary tumor and clinical nodal staging
Tx: primary tumor cannot be assessed
T0: no evidence of primary tumor
Tis: carcinoma in situ
Ta: noninvasive verrucous carcinoma
T1a: subepithelial connective tissue invasion, but no lymph vascular invasion
and not poorly differentiated
T1b: subepithelial connective tissue invasion with lymphovascular
invasion and/or poorly differentiated
T2: corpus spongiosum or cavernosum invasion
T3: urethral invasion
T4: invades other adjacent structures
Based on the American Joint Committee on cancer of penile carcinoma (201relationship of the lesion to the urethra and the clinical status
of the inguinal lymph nodes, which are the primary
lymphatic drainage of the penis. Brachytherapy requires
anesthesia and usually involves 5e6 days of hospitalization.
The patient’s general health, including cardiorespiratory
status, the presence of diabetes as a risk for delayed healing,
and the relative risk for thromboembolic disease should all
be assessed before the procedure. Imaging should include
a chest X-ray and CT scan of the abdomen and pelvis to eval-
uate the regional lymph nodes and rule out distant metas-
tasis. A CT scan is especially helpful for men with higher
body mass index where groin palpation is less reliable in de-
tecting adenopathy. All cases with moderately or poorly
differentiated disease, or clinical stage T2 or higher should
have CT or positron emission tomographyeCT staging.
Clinical evaluation of the primary tumor may underestimate
the depth of invasion, especially if biopsies are relatively
superficial. Therefore, imaging of the penis with either ultra-
sound or MRI with prostaglandin-induced erection can be
helpful in determining the extent of the primary tumor and
its relationship to the urethra. This information can assist
in brachytherapy catheter placement (12, 13).Patient selection
The disease staging system in Table 1 is the TNM
Seventh edition (2010) from the American Joint Committee
on Cancer Cancer Staging Manual (14). Stage Tis, Ta, or
T1a can be dealt with effectively using superficially abla-
tive, penile-sparing modalities such as CO2eneodymiume
yttriumealuminumegarnet (YAG) laser (15, 16). Such
early superficial lesions are usually not managed with bra-
chytherapy except in the case of recurrent or persistent
disease. Tumors that are of clinical stage T1b or T2 and less
than 4 cm in maximum diameter are most suitable for
primary brachytherapy. Lesions confined to the glans are
ideal but those with minor extension across the coronal
sulcus are also suitable provided the extension can be
covered with no more than one additional plane of needles.
If larger lesions are treated, especially those extending into
the corpora cavernosa, it must be understood by the patient
and referring physicians that there is higher risk of localNx: nodes cannot be assessed
N0: no palpable nodes or visible enlargement from imaging
N1: palpable mobile unilateral inguinal node
N2: palpable mobile multiple or bilateral inguinal nodes
N3: palpable fixed inguinal nodal mass or pelvic lymphadenopathy,
unilateral or bilateral
0).
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brachytherapy for management of the primary tumor may
present with early adenopathy or require sentinel lymph
node evaluation or inguinal node dissection. A combined
approach of brachytherapy for the primary and surgical
evaluation of lymph nodes can be considered.
T3 tumors with extension into the penile urethra are
generally not optimal candidates for brachytherapy,
although those cases where urethroscopy reveals submu-
cosal deformity without mucosal disruption may still be
treated with success, although there is however an
increased risk of meatal stenosis that should be explained
and understood by the patient. If a locally advanced
primary tumor presents with concomitant adenopathy, bra-
chytherapy is unlikely to play a role in management and
combinations of external beam radiotherapy (EBRT) with
chemotherapy  surgery should be considered (18).
Tumor grade is not an exclusion factor for brachytherapy
(19). In the 74 cases treated by Crook et al. (19) between
1989 and 2007, half had well-differentiated and the other
half had moderately or poorly differentiated cancer. Moder-
ately and poorly differentiated tumors responded as well as
those that were well differentiated. Local recurrences
occurred in six well-differentiated and two moderate-to-
poorly differentiated cases.Technical aspects
Penile brachytherapy is not a treatment modality that
needs to be available in every radiotherapy department.
A high volume and varied brachytherapy practice that
undertakes interstitial brachytherapy for other tumor
sites may wish to provide this treatment as the basic
principles are not dissimilar to those for other interstitial
implants. As this is an uncommon tumor, three to sixFig. 1. Schematic of a two-plane, six-needle implant showing the precases per year are sufficient to justify a program. Collab-
oration with a penile carcinoma center of excellence is
recommended.
Penile brachytherapy can be performed under general
anesthesia or penile block with systemic sedation. Antibi-
otic prophylaxis is optional. Low-dose-rate (LDR) brachy-
therapy consists of either manually afterloaded 192Ir or
pulse-dose-rate (PDR) brachytherapy. The latter uses auto-
mated afterloading with a high-intensity 192Ir source to
deliver hourly pulses. The two are similar in implant prin-
ciples and total dose. These implants should be clinically
designed according to the anatomic extent of tumor.
Knowledge of the Paris system of dosimetry (20) as shown
in Fig. 1 is a helpful guide for placement of sources so that
the prescription isodoses will encompass the visible and
palpable tumor with an appropriate margin. Because the
depth of invasion is often underappreciated, margins should
be generous and of 10 mm or greater in all directions
around the gross tumor volume to delineate the clinical
target volume.
The implant may be performed with a template or, if
properly stabilized, with other multicatheter interstitial
methods. The first step is insertion of a Foley catheter to
assist in urethral localization. Although the urethra can be
bracketed quite closely by the implant needles, it is essen-
tial to avoid transfixing it. The afterloading devices (carrier
needles or catheters) are inserted in parallel planes with
equal spacing to create a uniform volume implant orthogo-
nally to the longitudinal direction of the penis. Single-plane
implants are discouraged because the isodose at a depth
will be scalloped and may result in underdose to a part of
the tumor. Generally, two to three planes of needles or
catheters are sufficient (21). For the template technique,
individual needles (19.5 gauge for LDR and 17.5 gauge
for PDR) are held in a parallel array using predrilled
Lucite or plexiglass templates. When using brachytherapyscription isodose coverage according to the Paris system rules.
Fig. 3. High-dose-rate template with holes drilled on 3-mm centers to
allow flexibility of spacing.
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JacksonePratt drains or fixing buttons. Appropriate spacing
is chosen to cover the lesion, avoid the urethra, and provide
an adequate margin. For LDR or PDR implants, spacing of
12e18 mm is acceptable, but 14e16 mm is preferred.
Spacing should be equivalent between adjacent needles
and planes of needles. It should be noted that the closer
the spacing, the less the lateral margin of high dose
coverage lateral to the needles. Exterior planes of needles
or ‘‘plesiocurietherapy’’ (i.e., placed in space outside the
penis) can be used to ensure adequate coverage of the
surface and allow the most superficial of the ‘‘in-tissue’’
planes to be deep enough to avoid scarring or necrosis from
sources being too close to the skin. Tissue-equivalent bolus
is placed between the exterior plane and the tissue surface
to provide adequate radiation scatter (Fig. 2).
The high-dose-rate (HDR) implant procedure is techni-
cally similar to the LDR brachytherapy, but it is not
essential for the catheters to exactly follow a particular
spacing system because source loading and dwell time
adjustments (dosimetry optimization) can be used to
modulate the intensity of the radiation within the treat-
ment volume within a certain range. Closer spacing is
preferable for the HDR technique, generally 10e12 mm
between needles or catheters because it improves the
control and uniformity of the dosimetry. For instance, to
minimize central dose to the urethra, periurethral needles
can be more widely separated. A template that accommo-
dates this flexibility is shown in Fig. 3. Holes are
drilled on 3-mm centers (the closest possible to still have
the enough template material between the holes for
strength) allowing the needles to be spaced 9 or 12 mm
apart as required. The bridge keeps the two templates
parallel at all times. The parallel planes of needles can
be either staggered or superimposed. Similar catheter
spacing considerations can be applied to other stabiliza-
tion techniques.Fig. 2. A unilateral tumor allows some sparing of uninvolved glans. An
exterior plane of needles with bolus filling the gap to the penile surface
allows dose coverage at the surface without having to position needles
in tissue within 3 mm of the skin that can result in scarring and ulceration.Dosimetry
Dose prescription
Low-dose-rate/pulse-dose-rate brachytherapy. The rules
of the Paris system are well described and are well suited
to the template technique of penile brachytherapy (22).
The placement of the sources is clinically based, and the
completed implant is stable, which allows imaging for
dose calculation to be omitted. Such an approach assumes
that a standard implant distribution has been achieved, and
is maintained, and that standard dose calculations are per-
formed. Precise measurements, accurate to within 1 mm,
must be taken of the spacing between the templates and
of the active source lengths. The source placement for
each needle is known and confirmed by measurement of
the protrusion length of the needles on either side of the
templates. Dose calculations are then done for this stable
cubic array. In a nontemplate LDR or PDR technique,
images are essential for dosimetry. With PDR treatment
planning, some optimization can be introduced to mini-
mize the dips of the isodoses between the needle planes
in a template-guided technique (Fig. 4), or to compensate
for unequal spacing in a nontemplate technique. Accord-
ing to the Paris system, prescription for LDR and PDR
is to 85% of the dose rate minima between the planes.
The LDR prescribed dose is generally 60 Gy at
0.5e0.6 Gy/h with the treatment completed in about 5
days. For PDR treatments, pulses equivalent to the hourly
dose rate of an LDR implant are delivered every hour
(23e25).
Where remote afterloading is not available, manual
afterloading may be used with 192Ir radioactive sources in
the form of thin wires or plastic ribbons with seeds. Sources
are cut to the required length in the radioisotope room with
strict radiation protection including use of extremity and
whole body dosimeters, tweezers, and forceps for handling
of sources, and protective body shields. After each source
Fig. 4. Small glans can be covered with four needles without exceeding
18 mm spacing. Pulse-dose rate (PDR) allows some dose optimization that
decreases the amount of dose reduction between the implant planes. At left
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transported to the patient, the work area should be surveyed
and the source inventory logbook updated. Sources may be
loaded manually into the needles after the patient has been
transferred to the shielded room on the ward or in the oper-
ating room. For a full discussion of source handling and
precautions, see Ref. (21).
High-dose-rate brachytherapy. The literature on HDR 192Ir
brachytherapy for penile cancer is sparse. One published
experience involved mainly single-plane implants and used
twice daily fractions of 3.0 Gy to deliver 54 Gy over 9
consecutive days (26). Turning to unpublished experience
from experts in the field (AAM and DJD), we concluded
that fractionation of 3.2 Gy twice daily for a total of
38.4 Gy in 6 days for volume implants is well tolerated.
The interval between fractions should be at least 6 h. Penile
necrosis has been seen after doses of 42e45 Gy in 6 days
(3.5e3.75 Gy 12), but these doses may be tolerable if
attention is paid to dose homogeneity and the V125
(percentage of the planning target volume receiving 125%
of the prescribed dose) is kept lower than 40% and the
V150 kept lower than 20%. To decrease the incidence of
urethral strictures, the urethra V115 should be 10% or less
and the V90 less than 95% of the volume. Dose constraints
to the skin to minimize confluent areas greater than 125%
of the prescription will reduce the risk of necrosis. CT-
based planning is mandatory for HDR 192Ir penile brachy-
therapy, with three-dimensional delineation of the gross
tumor volume, clinical target volume, skin, and urethra
(Fig. 5). For treatment planning purposes, the patient is
scanned in the supine or lateral decubitus position. CT slice
thickness less than 2 mm and in-plane resolution lower than
0.5 mm are recommended to provide high-resolution
anatomic information and accurate needle localization. If
there is concern for penile edema or needle positioning,
repeat CT imaging may be performed during the course
to validate the geometry.Postimplant management
For LDR, PDR, or HDR, the patient remains in the
hospital for the duration of the implant. Bed rest is recom-
mended, but the implant is stable enough and often well
enough tolerated that the patient may ambulate for personal
necessities. The JacksonePratt drain or tube-and-button
system allow more mobility. In general, these implants
are well tolerated. Analgesia requirements may include
narcotic and/or non-narcotic medications. Antibiotics are
not routinely prescribed. The Foley catheter remains in
situ for the duration of the implant. Careful hygiene ofin each dose diagram is a low-dose-rate distribution resultant from the
Paris system of treatment planning using uniform source strength per unit
length. At right is the dose distribution from an optimized treatment plan
(PDR/high-dose rate) as used with modern computerized planning.
Fig. 5. High-dose-rate dosimetry for a six-needle implant with exterior plane and bolus. A second layer of bolus is placed lateral to (outside) the exterior
plane (the exterior plane is sandwiched between two layers of bolus).
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the patient is disinclined to ambulate, then antiembolic
stockings and low-dose heparin (5000 U every 12 h) or
low-molecular-weight heparin are recommended as
prophylaxis. The discontinuous pulses of PDR and HDR
implants facilitate nursing care and minimize exposure to
the personnel.
The implant can be removed either at the bedside with
sufficient analgesia or in the operating room with sedation.
Bleeding is usually minimal and can be controlled with
the application of light pressure. The patient can be dis-
charged the same day with home care instructions for
hygiene, which include daily soaks of the distal penis in
lukewarm water with the addition of baking soda or salt
in a receptacle such as a coffee mug. Moist desquamation
throughout the treated area is expected (Fig. 6) and usually
starts within 10e15 days. A loose tubular non-stick
dressing will prevent the healing skin from adhering to
underclothes. The site should not be tightly bandaged with
an occlusive dressing as this maneuver promotes infection
and delays healing. Multiagent antibiotic cream or ointmentFig. 6. Moist desquamation at 1 mo after high-dose-rate brachytherapy.can be applied for the first 2e4 weeks, and some authors
recommend that vitamin E ointment be applied later on
as re-epithelialization progresses. Complete healing usually
occurs within 2 months but in some cases may take 3e4
months or longer, especially in patients with diabetes
or vascular disease. Smoking is discouraged as it is
believed to delay wound healing. Intercourse can be
resumed when the patient is comfortable, although the heal-
ing epithelium is fragile, and extra water-based lubrication
is recommended.Clinical results
Table 2 shows a summary of the results in the literature
for LDR/PDR brachytherapy. Two of the more noteworthy
studies with large numbers of patients and mature followup
from single centers are those from de Crevoisier et al. (27)
and Crook et al. (19). In the report by Crook et al. (19),
actuarial local control and penile preservation at 5 years
were 87% and 88%, and at 10 years were 72% and 67%,
respectively. de Crevoisier et al. (27) reported penile pres-
ervation of 72% at 10 years. Because local failures can
occur even beyond 5 years, prolonged followup is manda-
tory. Of eight local failures, five occurred in the first 2 years
and the remaining three at 4.5, 7, and 8 years (19). With
continued surveillance, late local failures were successfully
managed surgically such that the 10-year cause-specific
survival was 84e90%. Grade is a strong predictor of
disease-free survival ( p 5 0.005). In the series of 67
patients of Crook et al. (19), 4% of well-differentiated
tumors recurred regionally or distantly as compared with
a 31% regional/distant recurrence rate for moderately or
poorly differentiated tumors (19).
A common approach to nodal management is to perform
clinical evaluation of the lymph nodes by palpation and CT
staging. In cases that were clinically and radiographically
node negative (N0), observation of the lymph nodes may
be selected; however, the presence of subclinical
Table 2
Clinical results of penile brachytherapy taken from the literature
References
Number
of patients
Dose
(Gy)
Mean followup
in mo (range)
% 5-Y local
control (y)
% 5-Y þ
cancer-specific
survival (y)a Complications
% Penile
preservation (y)
Chaudhary et al. (32) 23 50 21 (4e117) 70 (8) 0% Necrosis and 9% stenosis 70 (8)
de Crevoisier et al. (27) 144 65 68 (6e348) 80 (10) 92 (10) 26% Necrosis and 29% stenosis 72 (10)
Crook et al. (19) 67 60 48 (6e194) 87 (5) 72 (10) 83.6 (10) 12% Necrosis and 9% stenosis 88 (5) 67 (10)
Delannes et al. (33) 51 50e65 65 (12e144) 86 crude 85 23% Necrosis and 45% stenosis 75
Kiltie et al. (34) 31 63.5 61.5 81 85.4 8% Necrosis and 44% stenosis 75
Mazeron et al. (17) 50 60e70 36e96þ 78 crude 6% Necrosis and 19% stenosis 74
Rozan et al. (1) 184 63 139 86 88 21% Necrosis and 45% stenosis 78
Soria et al. (35) 102 61e70 111 77 72 Not stated 72 (6)
a Corrected for intercurrent deaths.
Fig. 7. Telangiectasia and area of hypopigmentation 6 years after pulse-
dose-rate brachytherapy.
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sulting in subsequent regional failure. Furthermore, delayed
management of clinically suspicious lymph nodes after a 6-
week course of antibiotics is also no longer advised. Rather,
ultrasound-guided fine-needle aspiration for cytology can
be used to investigate borderline or suspicious lymph nodes
(28). Crook et al. (19) recommend surgical staging using
either sentinel lymph node dissection, if the expertise is
available, or modified inguinal lymphadenectomy (13, 29,
30) for all moderately or poorly differentiated cancers
and for those well-differentiated tumors that are greater
than 4 cm or at clinical stage T2 or higher. Dynamic
sentinel lymph node dissection using patent blue dye and
gamma emission reduces the false-negative rate to less than
5% in experienced centers. Suitable primary brachytherapy
can be combined with surgical management of the lymph
nodes in a multidisciplinary approach. Postoperative EBRT
to the groins and pelvis can be offered to those patients with
multiple involved nodes or the presence of extracapsular
disease.
The most common late sequelae of penile brachytherapy
are soft tissue ulceration and urethral meatal stenosis.
Cosmesis is usually very good with minor areas of hypo-
or hyperpigmentation or telangiectasia (Fig. 7). Fibrosis is
limited to the area of the implant, and erectile function is
usually maintained because the corpora and shaft have
not been irradiated.
Nonhealing soft tissue ulceration beyond 3 months is re-
ported in 6e26% of cases, and is dependent on dose, tech-
nique, and tumor stage and volume. For LDR or PDR
brachytherapy, higher rates are associated with a higher
prescribed dose of 65 Gy (27), whereas ulceration rates
with 60 Gy are in the order of 12% (19). The risk is higher
with tumors greater than 4 cm in diameter and with a larger
number of needles. De Crevoisier et al. (27) have shown
that two factors predictive of complications were dose rate
higher than 0.6 Gy/h and treatment volume greater than
22 cm3. When using PDR, the dose rate can be adapted
by increasing the pulse frequency and decreasing the pulse
dose to keep the hourly dose rate at 0.6 Gy/h or lower.
Hyperbaric oxygen therapy can bring about speedy reso-
lution of ulceration when more conservative measures fail,although a prolonged series of ‘‘dives’’ over 6e8 weeks is
required (31).
Meatal stenosis is reported in 9e45% (1), but is related
to proximity of distal sources to the meatus. Crook et al.
(19) reported a rate of 9%, but routinely supplied patients
with a commercially available meatal dilator to be used
as required to deal with any impairment of urinary stream.
This may be beneficial in preventing problematic scarring
of the meatus.Conclusions
Brachytherapy provides excellent local control of
T1eT2 penile squamous cell carcinoma (and selected T3
lesions), ideally smaller than 4 cm with no or minimal
extension onto the penile shaft. Circumcision preceding
brachytherapy is essential. Penile conservation rates of
87% and 70% at 5 and 10 years, respectively, can be
achieved with brachytherapy. Lymph node observation is
appropriate for small (T1) well-differentiated tumors.
198 J.M. Crook et al. / Brachytherapy 12 (2013) 191e198Radiographic assessment and directed biopsies are war-
ranted in moderate or poorly differentiated or larger tumors.
Although surgical management of positive or suspicious
lymph nodes is preferred, EBRT is an option if the patient
is not a surgical candidate. Because local recurrence can
happen even after 5 years, extended followup is mandatory
because both local and regional failures can be salvaged
surgically. Meatal stenosis and soft tissue ulceration are
the most common significant late effects, but can be effec-
tively managed conservatively while retaining penis conser-
vation. LDR and PDR 192Ir brachytherapy fractionation is
well established with mature data in the literature. HDR
192Ir brachytherapy for penile cancer is under development.
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